+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antibody Drug Conjugates Global Market Opportunities and Strategies to 2033

  • PDF Icon

    Report

  • 303 Pages
  • July 2024
  • Region: Global
  • The Business Research Company
  • ID: 5982241
This report describes and explains the antibody drug conjugates market and covers 2018-2023, termed the historic period, and 2023-2028, 2033F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global antibody drug conjugates market reached a value of nearly $10.32 billion in 2023, having grown at a compound annual growth rate (CAGR) of 41.09% since 2018. The market is expected to grow from $10.32 billion in 2023 to $29.8 billion in 2028 at a rate of 23.60%. The market is then expected to grow at a CAGR of 21.21% from 2028 and reach $77.97 billion in 2033.

Growth in the historic period resulted from supportive policies and faster approval processes, increase in number of clinical trials and growing demand for antibody based cancer therapies. Factors that negatively affected growth in the historic period include challenges in identifying suitable targets for ADCs and lack of universal health coverage.

Going forward, the increasing prevalence and incidence of cancer, increasing aging population worldwide, rising healthcare expenditure globally and government programs and funding to support cancer research will drive the market. Factors that could hinder the growth of the antibody drug conjugates market in the future include high development costs.

The antibody drug conjugates market is segmented by linker type into cleavable linker and non-cleavable linker. The cleavable linker market was the largest segment of the antibody drug conjugates market segmented by linker type, accounting for 68.50% or $7.07 billion of the total in 2023. Going forward, the non-cleavable linker segment is expected to be the fastest growing segment in the antibody drug conjugates market segmented by linker type, at a CAGR of 24.82% during 2023-2028.

The antibody drug conjugates market is segmented by product into Kadcyla, Enhertu, Adcetris, Polivy, Trodelvy, Padcev and other products. The Kadcyla market was the largest segment of the antibody drug conjugates market segmented by product, accounting for 24.02% or $2.48 billion of the total in 2023. Going forward, the Polivy segment is expected to be the fastest growing segment in the antibody drug conjugates market segmented by product, at a CAGR of 34.64% during 2023-2028.

The antibody drug conjugates market is segmented by application into hematopoietic cancers, breast cancer, ovarian cancer, lung cancer, brain tumor and other applications. The breast cancer market was the largest segment of the antibody drug conjugates market segmented by application, accounting for 37.53% or $3.87 billion of the total in 2023. Going forward, the hematopoietic cancers segment is expected to be the fastest growing segment in the antibody drug conjugates market segmented by application, at a CAGR of 25.89% during 2023-2028.

The antibody drug conjugates market is segmented by end user into hospital and clinics, specialty centers and other end users. The hospital and clinics market was the largest segment of the antibody drug conjugates market segmented by end user, accounting for 58.59% or $6.05 billion of the total in 2023. Going forward, the hospitals and clinics segment is expected to be the fastest growing segment in the antibody drug conjugates market segmented by end user, at a CAGR of 25.07% during 2023-2028.

North America was the largest region in the antibody drug conjugates market, accounting for 40.67% or $4.2 billion of the total in 2023. It was followed by Western Europe, Asia-Pacific and then the other regions. Going forward, the fastest-growing regions in the antibody drug conjugates market will be Asia-Pacific and South America, where growth will be at CAGRs of 27.14% and 24.20% respectively. These will be followed by Western Europe and North America, where the markets are expected to grow at CAGRs of 23.14% and 22.75% respectively.

The global antibody drug conjugates market is highly concentrated, with large players dominating the market. The top ten competitors in the market made up to 99.26% of the total market in 2022. F. Hoffmann-La Roche Ltd. was the largest competitor with a 36.24% share of the market, followed by Daiichi Sankyo Company Limited with 25.59%, Seagen Inc. with 17.97%, Gilead Sciences Inc. with 8.86%, Genmab with 3%, Pfizer Inc. with 2.85%, GlaxoSmithKline plc with 1.62%, ADC Therapeutics SA with 1.37%, AstraZeneca plc with 1.03% and RemeGen with 0.74%.

The top opportunities in the antibody drug conjugates market segmented by linker type will arise in the cleavable linker segment, which will gain $12.86 billion of global annual sales by 2028. The top opportunities in the antibody drug conjugates market segmented by application will arise in the hematopoietic cancer segment, which will gain $5.19 billion of global annual sales by 2028. The top opportunities in the antibody drug conjugates market segmented by end user will arise in the hospitals and clinics segment, which will gain $12.47 billion of global annual sales by 2028. The top opportunities in the antibody drug conjugates market segmented by product will arise in the Enhertu segment, which will gain $8.198.12 million of global annual sales by 2028. The antibody drug conjugates market size will gain the most in the USA at $6.67 billion.

Market-trend-based strategies for the antibody drug conjugates market include pursuing strategic partnerships to provide comprehensive solutions and advance their capabilities, investing in R&D to develop new ADCs products and developing new ADCs with new mAB targets.

Player-adopted strategies in the antibody drug conjugates market include focus on enhancing operational capabilities through strategic partnerships.

To take advantage of the opportunities, the analyst recommends the antibody drug conjugates companies to focus on developing novel ADCs with enhanced specificity, focus on non-cleavable linker segment, focus on hematopoietic cancer segment, expand in emerging markets, focus on strategic partnerships for enhanced capabilities, focus on prioritize r&d investment for competitive advantage, provide competitively priced offerings, focus on value-based pricing strategies for antibody drug conjugates, participate in trade shows and events, continue to use B2B promotions, prioritize educational content and thought leadership, focus on targeting specific disease applications and focus on effectively targeting end users.

Table of Contents

1 Executive Summary
1.1 Antibody Drug Conjugates - Market Attractiveness and Macro economic Landscape
2 Table of Contents3 List of Tables4 List of Figures5 Report Structure
6 Market Characteristics
6.1 General Market Definition
6.2 Summary
6.3 Antibody Drug Conjugates Market Definition and Segmentations
6.4 Market Segmentation by Linked Type
6.4.1 Cleavable Linker
6.4.2 Non-cleavable Linker
6.5 Market Segmentation by Product
6.5.1 Adcetris
6.5.2 Kadcyla
6.5.3 Enhertu
6.5.4 Polivy
6.5.5 Trodelvy
6.5.6 Padcev
6.5.7 Other Products
6.6 Market Segmentation by Application
6.6.1 Hematopoietic Cancers
6.6.2 Breast Cancer
6.6.3 Lung Cancer
6.6.4 Brain Tumor
6.6.5 Ovarian Cancer
6.6.6 Other Applications
6.7 Market Segmentation by End User
6.7.1 Hospitals and Clinics
6.7.2 Specialty Centers
6.7.3 Other End-Users
7 Major Market Trends
7.1 Strategic Partnerships and Collaborations Among Market Players
7.2 Significant Investments in R&D by Market Players
7.3 Focus on New mAb Targets for ADCs Development
8 Antibody Drug Conjugates Market - Macro Economic Scenario
8.1 COVID-19 Impact on the Antibody Drug Conjugates Market
8.2 Impact of the War in Ukraine on the Antibody Drug Conjugates Market
8.3 Impact of High Inflation on the Antibody Drug Conjugates Market
9 Global Market Size and Growth
9.1 Market Size
9.2 Historic Market Growth, 2018 - 2023, Value ($ Million)
9.2.1 Market Drivers 2018 - 2023
9.2.2 Market Restraints 2018 - 2023
9.3 Forecast Market Growth, 2023 - 2028, 2033F Value ($ Million)
9.3.1 Market Drivers 2023 - 2028
9.3.2 Market Restraints 2023 - 2028
10 Global Antibody Drug Conjugates Market Segmentation
10.1 Global Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
10.2 Global Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
10.3 Global Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
10.4 Global Antibody Drug Conjugates Market, Segmentation by Product, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
11 Antibody Drug Conjugates Market, Regional and Country Analysis
11.1 Global Antibody Drug Conjugates Market, by Region, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
11.2 Global Antibody Drug Conjugates Market, by Country, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12 Asia-Pacific Market
12.1 Summary
12.2 Market Overview
12.2.1 Region Information
12.2.2 Market Information
12.2.3 Background Information
12.2.4 Government Initiatives
12.2.5 Regulations
12.2.6 Regulatory Bodies
12.2.7 Major Associations
12.2.8 Taxes Levied
12.2.9 Corporate Tax Structure
12.2.10 Investments
12.2.11 Major Companies
12.3 Asia-Pacific Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.4 Asia-Pacific Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.5 Asia-Pacific Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.6 Asia-Pacific Antibody Drug Conjugates Market: Country Analysis
12.7 China Market
12.8 Summary
12.9 Market Overview
12.9.1 Country Information
12.9.2 Market Information
12.9.3 Background Information
12.9.4 Government Initiatives
12.9.5 Regulations
12.9.6 Regulatory Bodies
12.9.7 Major Associations
12.9.8 Taxes Levied
12.9.9 Corporate Tax Structure
12.9.10 Investments
12.9.11 Major Companies
12.10 China Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.11 China Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.12 China Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.13 India Market
12.14 India Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.15 India Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.16 India Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.17 Japan Market
12.18 Japan Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.19 Japan Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.20 Japan Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.21 Australia Market
12.22 Australia Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.23 Australia Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.24 Australia Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.25 Indonesia Market
12.26 Indonesia Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.27 Indonesia Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.28 Indonesia Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.29 South Korea Market
12.30 South Korea Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.31 South Korea Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
12.32 South Korea Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13 Western Europe Market
13.1 Summary
13.2 Market Overview
13.2.1 Region Information
13.2.2 Market Information
13.2.3 Background Information
13.2.4 Government Initiatives
13.2.5 Regulations
13.2.6 Regulatory Bodies
13.2.7 Major Associations
13.2.8 Taxes Levied
13.2.9 Corporate Tax Structure
13.2.10 Investments
13.2.11 Major Companies
13.3 Western Europe Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.4 Western Europe Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.5 Western Europe Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.6 Western Europe Antibody Drug Conjugates Market: Country Analysis
13.7 UK Market
13.8 UK Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.9 UK Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.10 UK Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.11 Germany Market
13.12 Germany Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.13 Germany Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.14 Germany Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.15 France Market
13.16 France Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.17 France Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.18 France Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.19 Italy Market
13.20 Italy Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.21 Italy Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.22 Italy Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.23 Spain Market
13.24 Spain Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.25 Spain Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
13.26 Spain Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14 Eastern Europe Market
14.1 Summary
14.2 Market Overview
14.2.1 Region Information
14.2.2 Market Information
14.2.3 Background Information
14.2.4 Government Initiatives
14.2.5 Regulations
14.2.6 Regulatory Bodies
14.2.7 Major Associations
14.2.8 Taxes Levied
14.2.9 Corporate Tax Structure
14.2.10 Investments
14.2.11 Major Companies
14.3 Eastern Europe Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.4 Eastern Europe Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.5 Eastern Europe Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.6 Eastern Europe Antibody Drug Conjugates Market: Country Analysis
14.7 Russia Market
14.8 Russia Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.9 Russia Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
14.10 Russia Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15 North America Market
15.1 Summary
15.2 Market Overview
15.2.1 Region Information
15.2.2 Market Information
15.2.3 Background Information
15.2.4 Government Initiatives
15.2.5 Regulations
15.2.6 Regulatory Bodies
15.2.7 Major Associations
15.2.8 Taxes Levied
15.2.9 Corporate Tax Structure
15.2.10 Investments
15.2.11 Major Companies
15.3 North America Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.4 North America Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.5 North America Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.6 North America Antibody Drug Conjugates Market: Country Analysis
15.7 USA Market
15.8 Summary
15.9 Market Overview
15.9.10 Country Information
15.9.2 Market Information
15.9.3 Background Information
15.9.4 Government Initiatives
15.9.5 Regulations
15.9.6 Regulatory Bodies
15.9.7 Major Associations
15.9.8 Taxes Levied
15.9.9 Corporate Tax Structure
15.9.10 Investments
15.9.11 Major Companies
15.10 USA Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.11 USA Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.12 USA Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.13 Canada Market
15.14 Canada Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.15 Canada Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
15.16 Canada Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16 South America Market
16.1 Summary
16.2 Market Overview
16.2.1 Region Information
16.2.2 Market Information
16.2.3 Background Information
16.2.4 Government Initiatives
16.2.5 Regulations
16.2.6 Regulatory Bodies
16.2.7 Major Associations
16.2.8 Taxes Levied
16.2.9 Corporate Tax Structure
16.2.10 Major Companies
16.3 South America Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.4 South America Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.5 South America Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.6 South America Antibody Drug Conjugates Market: Country Analysis
16.7 Brazil Market
16.8 Brazil Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.9 Brazil Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
16.10 Brazil Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
17 Middle East Market
17.1 Summary
17.2 Market Overview
17.2.1 Region Information
17.2.2 Market Information
17.2.3 Background Information
17.2.4 Government Initiatives
17.2.5 Regulations
17.2.6 Regulatory Bodies
17.2.7 Major Associations
17.2.8 Taxes Levied
17.2.9 Corporate Tax Structure
17.2.10 Major Companies
17.3 Middle East Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
17.4 Middle East Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
17.5 Middle East Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
18 Africa Market
18.1 Summary
18.2 Market Overview
18.2.1 Region Information
18.2.2 Market Information
18.2.3 Background Information
18.2.4 Government Initiatives
18.2.5 Regulations
18.2.6 Regulatory Bodies
18.2.7 Major Associations
18.2.8 Taxes Levied
18.2.9 Corporate Tax Structure
18.2.10 Major Companies
18.3 Africa Antibody Drug Conjugates Market, Segmentation by Linker Type, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
18.4 Africa Antibody Drug Conjugates Market, Segmentation by Application, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
18.5 Africa Antibody Drug Conjugates Market, Segmentation by End User, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
19 Competitive Landscape and Company Profiles
19.1 Company Profiles
19.1 F. Hoffman-La Roche Ltd
19.1.1 Company Overview
19.1.2 Products and Services
19.1.3 Business Strategy
19.1.4 Financial Overview
19.2 Daiichi Sankyo Company Limited
19.2.1 Company Overview
19.2.2 Products and Services
19.2.3 Business Strategy
19.2.4 Financial Overview
19.3 Seagen Inc
19.3.1 Company Overview
19.3.2 Products and Services
19.3.3 Business Strategy
19.3.4 Financial Overview
19.4 Gilead Sciences Inc
19.4.1 Company Overview
19.4.2 Products and Services
19.4.3 Business Strategy
19.4.4 Financial Overview
19.5 Genmab a/S
19.5.1 Company Overview
19.5.2 Products and Services
19.5.3 Business Strategy
19.5.4 Financial Overview
20 Other Major and Innovative Companies
20.1 Pfizer
20.1.1 Company Overview
20.1.2 Products and Services
20.2 GlaxoSmithKline plc
20.2.1 Company Overview
20.2.2 Products and Services
20.3 ADC Therapeutics SA
20.3.1 Company Overview
20.3.2 Products and Services
20.4 AstraZeneca plc
20.4.1 Company Overview
20.4.2 Products and Services
20.5 RemeGen
20.5.1 Company Overview
20.5.2 Products and Services
20.6 Astellas Pharma Inc.
20.6.1 Company Overview
20.6.2 Products and Services
20.7 ImmunoGen Inc.
20.7.1 Company Overview
20.7.2 Products and Services
20.8 Rakuten Medical
20.8.1 Company Overview
20.8.2 Products and Services
20.9 Takeda Pharmaceutical Company Limited
20.9.1 Company Overview
20.9.2 Products and Services
20.10 AbbVie Inc.
20.10.1 Company Overview
20.10.2 Products and Services
20.11 Mersana Therapeutics Inc.
20.11.1 Company Overview
20.11.2 Products and Services
20.12 Merck Co. & KGaA
20.12.1 Company Overview
20.12.2 Products and Services
20.13 Bristol Myers Squibb Co.
20.13.1 Company Overview
20.13.2 Products and Services
20.14 Novo Nordisk a/S
20.14.1 Company Overview
20.14.2 Products and Services
20.15 Bayer AG
20.15.1 Company Overview
20.15.2 Products and Services
21 Competitive Benchmarking22 Competitive Dashboard
23 Key Mergers and Acquisitions
23.1 Genmab a/S Acquired ProfoundBio Inc
23.2 Johnson & Johnson (J&J) Acquired Ambrx Biopharma Inc
23.3 AbbVie Acquired ImmunoGen, Inc
23.4 Pfizer Inc Acquired Seagen Inc
24 Opportunities and Strategies
24.1 Global Antibody Drug Conjugates Market in 2028 - Countries Offering Most New Opportunities
24.2 Global Antibody Drug Conjugates Market in 2028 - Segments Offering Most New Opportunities
24.3 Global Antibody Drug Conjugates Market in 2028 - Growth Strategies
24.3.1 Market Trend Based Strategies
24.3.2 Competitor Strategies
25 Antibody Drug Conjugates Market, Conclusions and Recommendations
25.1 Conclusions
25.2 Recommendations
25.2.1 Product
25.2.2 Place
25.2.3 Price
25.2.4 Promotion
25.2.5 People
26 Appendix
26.1 Geographies Covered
26.2 Market Data Sources
26.3 Research Methodology
26.4 Currencies
26.5 About the Analyst
26.6 Copyright and Disclaimer

Executive Summary

Antibody Drug Conjugates Global Market Opportunities and Strategies to 2033 provides the strategists; marketers and senior management with the critical information they need to assess the global antibody drug conjugates market as it emerges from the COVID-19 shut down.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Description

Where is the largest and fastest-growing market for antibody drug conjugates? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The antibody drug conjugates market global report answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider antibody drug conjugates market; and compares it with other markets.

The report covers the following chapters:

  • Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by linker type, by product, by application and by end-user.
  • Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
  • Macro-Economic Scenario - The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the antibody drug conjugates market.
  • Global Market Size and Growth - Global historic (2018-2023) and forecast (2023-2028, 2033F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
  • Regional and Country Analysis - Historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison by region and country.
  • Market Segmentation - Contains the market values (2018-2023) (2023-2028, 2033F) and analysis for each segment by linker type, by product, by application and by end-user in the market. Historic (2018-2023) and forecast (2023-2028) and (2028-2033) market values and growth and market share comparison by region market.
  • Regional Market Size and Growth - Regional market size (2023), historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
  • Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
  • Other Major and Innovative Companies Details on the company profiles of other major and innovative companies in the market.
  • Competitive Benchmarking - Briefs on the financials comparison between major players in the market.
  • Competitive Dashboard - Briefs on competitive dashboard of major players.
  • Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
  • Market Opportunities and Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
  • Conclusions and Recommendations - This section includes recommendations for antibody drug conjugates providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
  • Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

1) by Linker Type: Cleavable Linker; Non-Cleavable Linker
2) by Product: Kadcyla; Enhertu; Adcetris; Polivy; Trodelvy; Padcev; Other Products
3) by Application: Hematopoietic Cancers; Breast Cancer; Ovarian Cancer; Lung Cancer; Brain Tumor; Other Applications
4) by End User: Hospital; Clinics; Specialty Centers; Other End Users

Key Companies Mentioned: F. Hoffmann-La Roche Ltd.; Daiichi Sankyo Company Limited; Seagen Inc.; Gilead Sciences Inc.; Genmab

Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; Italy; Spain; UK; Russia

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; antibody drug conjugates indicators comparison.

Data Segmentation: Country and regional historic and forecast data; market share of competitors; market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Companies Mentioned

  • F. Hoffmann-La Roche Ltd.
  • Daiichi Sankyo Company Limited
  • Seagen Inc.
  • Gilead Sciences Inc.
  • Genmab
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • ADC Therapeutics SA
  • AstraZeneca plc
  • RemeGen
  • Medilink Therapeutics
  • Hansoh Pharmaceutical Group
  • Biotheus
  • Shanghai Miracogen Inc.
  • WuXi Biologics
  • Shanghai Henlius Biotech, Inc.
  • Ascentage Pharma
  • Takeda Pharmaceutical Company Limited
  • Zydus Lifesciences Limited
  • Eisai Co. Ltd.
  • Piramal Pharma Solutions
  • Sanofi
  • Bayer AG
  • Heidelberg Pharma AG
  • Merck KGaA
  • Oxford BioTherapeutics
  • JSC BIOCAD
  • Pharmstandard
  • Selvita
  • Sotio
  • Generium
  • Polpharma Biologics
  • AdamedZentiva
  • Biofarm
  • Rompharm Company
  • Celldex Therapeutics Inc.
  • Concortis Biotherapeutics Corp.
  • Sorrento Therapeutics Inc.
  • Regeneron Pharmaceuticals Inc.
  • Millennium Pharmaceuticals Inc.
  • AbbVie Inc
  • Johnson & Johnson
  • Ambrx
  • Mersana Therapeutics Inc.
  • Merck & Co., Inc.
  • BeiGene
  • DualityBio
  • ImmunoGen, Inc.
  • ImmunoBiochem
  • Recepta Biopharma S.A.
  • Procaps Group, S.A.
  • Fiocruz
  • Eurofarma Laboratórios S.A.
  • Gen-t
  • InEDITA Bio
  • Vyro Biotherapeutics
  • Laboratorios Bagó SA
  • Gador S.A.
  • Roemmers SAICF
  • Astellas Pharma Inc
  • Aspen Pharmacare Holdings
  • Adcock Ingram
  • Egyptian Pharmaceutical Company
  • Hikma Pharmaceuticals
  • Pharmacare Limited
  • Fidson Healthcare Plc
  • May & Baker Nigeria Plc
  • Ethiopian Pharmaceuticals Manufacturing Sh. Co.
  • Biofem Pharmaceuticals Ltd
  • Beta Healthcare International

Methodology

Loading
LOADING...

Table Information